LLA Stock Overview
A diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LungLife AI, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.30 |
| 52 Week High | UK£0 |
| 52 Week Low | UK£0 |
| Beta | -0.30 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| LLA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 0.8% |
| 1Y | n/a | -21.1% | 10.8% |
Return vs Industry: Insufficient data to determine how LLA performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how LLA performed against the UK Market.
Price Volatility
| LLA volatility | |
|---|---|
| LLA Average Weekly Movement | 0% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: LLA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LLA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 15 | Paul Pagano | lunglifeai.com |
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People’s Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019.
LungLife AI, Inc. Fundamentals Summary
| LLA fundamental statistics | |
|---|---|
| Market cap | UK£4.45m |
| Earnings (TTM) | -UK£4.24m |
| Revenue (TTM) | UK£36.05k |
123.3x
P/S Ratio-1.0x
P/E RatioIs LLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLA income statement (TTM) | |
|---|---|
| Revenue | US$46.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$46.00k |
| Other Expenses | US$5.46m |
| Earnings | -US$5.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | -11,767.39% |
| Debt/Equity Ratio | 0% |
How did LLA perform over the long term?
See historical performance and comparison